Pediatrix Medical Group walked into its Q3 2026 report with the stock quietly grinding higher over the past month, then picked up another 2.2% in the first trading session after the release. On the surface that looks like a modest cheer, not a frenzy. Yet the earnings story is bigger than a one day bump, with basic earnings per share at about $0.59 and adjusted EBITDA at $85.5 million, and investors weighing whether this move finally reflects growing confidence in a still pressured margin profile.
Like the Pediatrix Medical Group earnings setup but uneasy about the still pressured margin profile behind that $85.5 million in adjusted EBITDA? Check out the list of solid balance sheet and fundamentals stocks (25 results) .
Q3 2026 Earnings Summary
-
Total Revenue (Q3 2026 vs. Q3 2025):US$501.4 million vs. US$492.9 million (+1.7%)
-
Net Income (Excl. Extra Items, Q3 2026 vs. Q3 2025):US$47.0 million vs. US$71.7 million (declined 34.5%)
-
Basic EPS (Q3 2026 vs. Q3 2025):US$0.59 vs. US$0.85 (fell 30.4%)
-
Trailing 12-Month Net Profit Margin (Q3 2026 vs. prior year):7.7% vs. 8.4% (compressed 0.7 percentage points)
Prefer clear visuals instead of another dense page of Pediatrix Medical Group numbers? See the whole story on margins and earnings quality in a streamlined, chart-driven view through our company report for Pediatrix Medical Group.
Pediatrix pricing thesis clears key Q3 hurdles
The bullish pitch on Pediatrix Medical Group hangs on earnings resilience built on reimbursement and cost control rather than raw patient counts.
"The main thing that has to go right is that Pediatrix Medical Group continues to offset flat-to-declining NICU and patient service volumes with resilient payer mix, efficient revenue cycle management, and controlled G&A and salary costs."
Q3 hits several of those checkpoints. Same unit growth came from a roughly even mix of pricing and modest volume, with payer mix and hospital fees doing meaningful work. Salaries are running near the targeted ~3% range and G&A increased but stayed manageable. EBITDA guidance tightened to US$290m to US$300m, which supports the resilience claim for now, even as operating cash flow softened year on year.
One Narrative has put a figure on that disagreement. → See the Narrative with its lower Fair Value, assumptions and all .
Bear Case On Fading Pricing Power Meets Mixed Evidence
The bearish worry is clear. Pediatrix Medical Group is seen as increasingly dependent on price per encounter, not more babies in beds.
"While Pediatrix Medical Group is currently sustaining revenue growth through higher pricing supported by improved collections, payer mix and neonatal acuity, management already expects the revenue cycle tailwind to fade in the second half of 2026."
Q3 results partially validate that concern. Same unit pricing only added 30 bps after roughly 100 bps of RCM benefit rolled off. Yet same unit volume contributed a similar 30 bps and NICU days stayed stable, so the feared volume drag did not materialize this quarter. EBITDA guidance tightening to US$290m to US$300m suggests cost discipline is holding for now, but pricing no longer looks like a one way lever.
Hunt For Quiet Mispricings
Pediatrix Medical Group just reminded you that a decent quarter and a modest stock reaction can still leave plenty of debate. The real opportunity is spotting companies that could be undervalued before fresh information closes the gap.
-
Company 1 - 34% below our estimate - uses long term optical and solar supply contracts and customer prepayments to turn infrastructure spending into higher margin manufacturing runs.
-
Company 2 - 47% below our estimate - pours heavy AI data center spending into ad tools and business messaging products that change how marketers target and convert users.
-
Company 3 - 35% below our estimate - relies on dominance in GPU design and a tightly controlled AI software stack to capture data center build outs.
That is three of the list. See all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include MD .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
